This discrepancy is just not shared with other dopamine reuptake inhbitors like bupropion, sibutramine, mazindol or tesofensine, which have related or larger potencies than copyright as dopamine reuptake inhibitors. These findings have evoked a hypothesis that copyright may function for a so-identified as "DAT inverse agonist" or "negative alloster